5 hours Castle Biosciences (CSTL) Upgraded to Strong Buy: Here’s WhyZacks
Castle Biosciences (CSTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
X NYSE Nasdaq 100 Earnings Tech U.S. Science SEC Politics AI Business Energy Dow Jones Wall Street Dividend Investing Markets Crude Oil China Economy S&P 500 Wealth Bitcoin (BTC) World Fed NVIDIA (NVDA) Real Estate Health Tesla (TSLA) Software 3M (MMM) Insurance Gold Money Natural Gas Inflation Canada Entertainment Apple (AAPL) U.K. Options Pharmaceuticals Amazon (AMZN) Boeing (BA) Security Donald Trump Construction Retail Meta Platforms (META) Europe Current Microsoft (MSFT) Hedge Funds Jim Cramer Retirement JPMorgan (JPM) Mining Taxes Manufacturing Google Goldman Sachs (GS) Wells Fargo&Co (WFC) Truist Financial Corp (TFC) Elon Musk Netflix (NFLX) Finance Sports Aerospace Tax Bank of America (BAC) Morgan Stanley (MS) Cars Silver York New York Enterprise Japan Live REITs Airlines Interest Rates Israel Kamala Harris Internet Costco (COST) Economics Space Mortgage Property Milton Florida Texas Warren Buffett IPOs War Boston Intel (INTC) Compound (COMP) BlackRock (BLK) AMD (AMD) ASML (ASML)More +
